Imunon, Inc. Common Stock

Day range

$1.20 – $1.27

Open

$1.25

Prev close

$1.24

Volume

30.09K

Market cap

$6.93M

Shares out

5.61M

P/E

—

P/S

—

P/B

1.66

P/FCF

—

ROE

-351.7%

ROA

-98.3%

Debt/Equity

1.68

Div yield

0.00%

As of Oct 23, 2026

• Divestiture agreementOct 21, 2026

  On October 20, 2026, Imunon, Inc. entered into an Asset Purchase Agreement with VoxelDox Therapeutics, Inc., pursuant to which the Company agreed to sell to VoxelDox the Company's assets relating to ThermoDox®, including related trademarks, regulatory filings, clinical and preclinical data, manufacturing know-how and existing drug product vials.

• Cfo appointmentJun 30, 2026

  As a result of Mr. Church's retirement, effective July 1, 2026, the Company appointed Josh Blacher to serve as the Company's new interim Chief Financial Officer under a master services agreement (the "Agreement"), dated June 24, 2026, between the Company and Danforth Health, Inc., a financial advisory services firm ("Danforth"). Mr. Blacher will serve as the Company's principal financial officer and principal accounting officer.

• Equity compensation grantJun 16, 2026

  The amendment increased the aggregate number of shares of common stock that may be delivered pursuant to all awards granted under the Plan by an additional 1,000,000 shares so that the new aggregate share limit for the Plan is 1,265,004 shares.

• Private placementJun 4, 2026

  On June 2, 2026, Imunon, Inc. entered into a securities purchase agreement with Streeterville Capital, LLC, providing for the issuance and sale by the Company of 250 shares of Series A Preferred Stock at a price of $10,000 per share, for aggregate proceeds of $2,500,000. The Preferred Shares were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.

• Executive compensation changeMay 4, 2026

  On May 1, 2026, Imunon, Inc. entered into change of control agreements with Stacy Lindborg (Chief Executive Officer and President), Douglas Faller (Chief Medical Officer), and Susan Eylward (General Counsel and Corporate Secretary), to provide severance benefits to these executives should their employment terminate in certain circumstances in connection with a change in control of the Company.

Days to cover

1.2

Short interest

173.2K

Avg volume

142.35K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
  neutralGlobeNewswire Inc.· Mar 24, 2026
• IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call
  positiveGlobeNewswire Inc.· Aug 5, 2025
• IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
  positiveGlobeNewswire Inc.· May 23, 2025
• IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer
  GlobeNewswire Inc.· Jun 24, 2024
• First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial
  GlobeNewswire Inc.· Jun 5, 2024